The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Abbott achieved a regulatory first in diabetes care that no rival has matched, but the article notes the stock is still well below its level a year ago. The key issue is how much additional proof (commercial uptake, data, or further approvals) is required to close the valuation gap implied by that underperformance.